The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery
- PMID: 3687582
- DOI: 10.1007/BF01966492
The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery
Abstract
Studies were conducted to evaluate the use of a murine SLE-like disease for the discovery of novel drugs: This disease is the result of a chronic form of a graft vs host (GVH) reaction. Using prednisolone (Pr), cyclophosphamide (Cy), indomethacin (Indo), and the isoxazol derivative, HWA 486, we found that only Indo was ineffective in inhibiting the SLE symptoms. Interestingly, HWA 486, which did not display any immunosuppressive activity, restored the suppressed T-cell response to the same level as found in healthy mice. We feel that this murine model of SLE could be of value for discovering substances with novel antirheumatic, and/or immunomodulating activities.
Similar articles
-
Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.Agents Actions. 1991 Jan;32(1-2):10-21. doi: 10.1007/BF01983301. Agents Actions. 1991. PMID: 2058454 Review.
-
Leflunomide: friend or foe for systemic lupus erythematosus?Rheumatol Int. 2013 Feb;33(2):273-6. doi: 10.1007/s00296-012-2508-z. Epub 2012 Sep 8. Rheumatol Int. 2013. PMID: 22961090 Review.
-
Murine chronic graft-versus-host disease as a model of systemic lupus erythematosus: effect of immunosuppressive drugs on disease development.Clin Exp Immunol. 1989 Dec;78(3):449-53. Clin Exp Immunol. 1989. PMID: 2612055 Free PMC article.
-
Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease.Scand J Rheumatol Suppl. 1988;75:290-9. doi: 10.3109/03009748809096781. Scand J Rheumatol Suppl. 1988. PMID: 3238364
-
Analysis of changes in joint function and peripheral blood mononuclear cells in patients with systemic lupus erythematosus and intervention effects of different drugs.Eur Rev Med Pharmacol Sci. 2017 Oct;21(19):4423-4430. Eur Rev Med Pharmacol Sci. 2017. PMID: 29077150 Clinical Trial.
Cited by
-
Pharmacologic manipulation of graft versus host induced splenomegaly.Agents Actions. 1992 Mar;35(3-4):260-7. doi: 10.1007/BF01997509. Agents Actions. 1992. PMID: 1529801
-
Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection.Agents Actions. 1991 Jan;32(1-2):10-21. doi: 10.1007/BF01983301. Agents Actions. 1991. PMID: 2058454 Review.
-
Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide.Clin Exp Immunol. 1999 Feb;115(2):221-8. doi: 10.1046/j.1365-2249.1999.00777.x. Clin Exp Immunol. 1999. PMID: 9933446 Free PMC article.
-
The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.PLoS One. 2015 Dec 15;10(12):e0144548. doi: 10.1371/journal.pone.0144548. eCollection 2015. PLoS One. 2015. PMID: 26670616 Free PMC article.
-
Leflunomide: friend or foe for systemic lupus erythematosus?Rheumatol Int. 2013 Feb;33(2):273-6. doi: 10.1007/s00296-012-2508-z. Epub 2012 Sep 8. Rheumatol Int. 2013. PMID: 22961090 Review.
References
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials